Skip to main content
Clinical Trials/NCT02335476
NCT02335476
Unknown
Not Applicable

Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography

National Taiwan University Hospital1 site in 1 country100 target enrollmentMarch 2015
ConditionsMelanoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Melanoma
Sponsor
National Taiwan University Hospital
Enrollment
100
Locations
1
Primary Endpoint
Ex vivo Tissue image.
Last Updated
9 years ago

Overview

Brief Summary

The investigators will use optical coherence tomography to detect the ex-vivo tissue image of surgical removed melanoma or other benign pigmented lesions of skin.

Detailed Description

The investigators will use an advanced high resolution 3D optical coherence tomography (OCT) technology to observe skin tissue images in ex vivo culture. Parts of melanoma or benign pigmented lesions specimens derived from biopsy or surgical excision specimen will be observed by 3D optical tomography. A tiny tissue fragment of melanoma or benign pigmented lesions will be taken from surgical specimen without interference normal pathological evaluation. The location of melanocytic cells in melanoma or benign tissue fragments will be mapped by the 3D optical coherence tomography (OCT). The 3D optic tomography system utilize a Ce:YAG optical fiber as light source and also combined with confocal microscopy. Taken together, these features made the 3D optic tomography system have very high resolution and suitable for single cell imaging. This study will not interfere with the normal medical practice and had no impact on patient's safety and health. All of the materials will be destroyed once the experiments are done. The enrollment criteria will be dermatological patients who need to surgical intervention.

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
April 2017
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients aged older than 20 years old
  • Patients who had melanoma, melanoma in situ, and/or other benign pigmented lesions,
  • Patients who had non-melanoma skin cancers (basal cell carcinoma, or squamous cell carcinoma).
  • Patients who had precancerous skin lesions (Bowen's disease, actinicc keratosis)

Exclusion Criteria

  • Pregnant women.

Outcomes

Primary Outcomes

Ex vivo Tissue image.

Time Frame: 1 day

Partial fragments of tissue specimens from melanoma, melanoma in situ, or other benign pigmented lesions will be used for imaging purpose by a optical coherence tomography.

Study Sites (1)

Loading locations...

Similar Trials